RXi Pharmaceuticals Corp. (NASDAQ:RXII) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.34) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.34). During the same period last year, the business earned ($0.40) EPS.

Shares of RXi Pharmaceuticals Corp. (NASDAQ:RXII) opened at 1.02 on Thursday. The stock has a 50 day moving average price of $1.43 and a 200 day moving average price of $2.06. RXi Pharmaceuticals Corp. has a 12 month low of $0.94 and a 12 month high of $4.46. The stock’s market cap is $6.69 million.

Earnings History for RXi Pharmaceuticals Corp. (NASDAQ:RXII)

Separately, Zacks Investment Research downgraded RXi Pharmaceuticals Corp. from a “buy” rating to a “hold” rating in a research report on Friday, July 15th.

About RXi Pharmaceuticals Corp.

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

5 Day Chart for NASDAQ:RXII

Receive News & Stock Ratings for RXi Pharmaceuticals Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corp. and related stocks with our FREE daily email newsletter.